Souweidane Mark M, Morgenstern Peter F, Christos Paul J, Edgar Mark A, Khakoo Yasmin, Rutka James T, Dunkel Ira J
Department of Neurological Surgery, Weill Cornell Medical College, and Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neurosurgery. 2009 Jul;65(1):72-8; discussion 78. doi: 10.1227/01.NEU.0000348011.98625.43.
This study was conducted to determine whether arachnoid tissue or cerebrospinal fluid (CSF) sampling is valuable for risk stratification in children with posterior fossa brain tumors.
Arachnoid tissue and CSF from the cisterna magna (CSFCM) was sampled at the time of primary tumor resection. Results were compared with conventional staging methods (M stage) and correlated with patient outcome.
Eighty-three patients were enrolled in the study. Arachnoid infiltration was identified in 11 of 80 (13.8%) and CSFCM was positive in 20 of 77 (26.0%) specimens. Arachnoid infiltration and CSF cytology were found in 20.0% and 44.8%, respectively, for medulloblastoma/pineoblastoma (primitive neuroectodermal tumor), 6.9% and 3.6% for pilocytic astrocytoma, and 0.0% and 33.3% for ependymoma. The 3-year event-free survival (EFS) was negatively influenced by either arachnoid infiltration (40.9% arachnoid positive versus 65.4% arachnoid negative; P = 0.23) or CSFCM positivity (52.6% CSFCM positive versus 67.1% CSFCM negative; P = 0.03). The 3-year EFS for patients with primitive neuroectodermal tumor who had positive arachnoid sampling was 33.3%, compared with 67.3% in patients who had no evidence of arachnoid infiltration (P = 0.26). The 3-year EFS for patients with primitive neuroectodermal tumor who had positive CSFCM was 50.0% compared with 67.5% in patients who had negative cytological analysis of CSFCM (P = 0.07). Arachnoid infiltration and CSF sampling were congruous with M stage in 73.3% and 86.2% of patients, respectively.
Intraoperative evidence of arachnoid infiltration or CSFCM dissemination in patients with posterior fossa brain tumors occurs at a variable frequency that is dependent on tumor type, correlates with conventional M stage, and may be predictive of outcome.
本研究旨在确定蛛网膜组织或脑脊液(CSF)采样对后颅窝脑肿瘤患儿的风险分层是否有价值。
在原发性肿瘤切除时采集蛛网膜组织和小脑延髓池脑脊液(CSFCM)。将结果与传统分期方法(M分期)进行比较,并与患者预后相关联。
83例患者纳入本研究。80例中有11例(13.8%)发现蛛网膜浸润,77例中有20例(26.0%)CSFCM呈阳性。髓母细胞瘤/松果体母细胞瘤(原始神经外胚层肿瘤)中蛛网膜浸润和CSF细胞学检查阳性率分别为20.0%和44.8%,毛细胞型星形细胞瘤为6.9%和3.6%,室管膜瘤为0.0%和33.3%。蛛网膜浸润(蛛网膜阳性者3年无事件生存率为40.9%,蛛网膜阴性者为65.4%;P = 0.23)或CSFCM阳性(CSFCM阳性者3年无事件生存率为52.6%,CSFCM阴性者为67.1%;P = 0.03)均对3年无事件生存率(EFS)产生负面影响。蛛网膜采样阳性的原始神经外胚层肿瘤患者3年EFS为33.3%,而无蛛网膜浸润证据的患者为67.3%(P = 0.26)。CSFCM阳性的原始神经外胚层肿瘤患者3年EFS为50.0%,而CSFCM细胞学分析阴性的患者为67.5%(P = 0.07)。蛛网膜浸润和CSF采样分别与73.3%和86.2%的患者M分期一致。
后颅窝脑肿瘤患者术中蛛网膜浸润或CSFCM播散的证据出现频率不一,取决于肿瘤类型,与传统M分期相关,且可能预测预后。